Lisocabtagene maraleucel is a CAR T-cell therapy for treatment resistant or more severe B-cell lymphomas. Lisocabtagene maraleucel is a chimeric antigen receptor (CAR) T-cell therapy, similar to brexucabtagene autoleucel and axicabtagene ciloleucel.
- Mechanism
- Curator reviewed · 8 references
Lisocabtagene maraleucel is chimeric antigen receptor (CAR) T-cell therapy that targets CD19, also known as the B-lymphocyte surface antigen B4. The CAR is composed of an FMC63 monoclonal antibody single chain variable fragment, IgG4 hinge region, CD28 transmembrane domain, 4-1BB costimulatory domain, and CD3ζ activation domain. FMC63 is an IgG2a mouse monoclonal antibody that targets CD19. The IgG4 hinge region can interact with Fcγ receptors to modulate the response of hematopoietic cells. The CD28 transmembrane domain can stimulate the activity or tolerance of T-cells. 4-1BB enhances cytotoxic T-cell activity as well as the production of interferon-γ. The CD23ζ cytoplasmic domain mediates T-cell activation by CD2, a T-cell surface adhesion molecule.
- Primary indication
- Lisocabtagene maraleucel is indicated to treat adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell...Curator reviewed · 20 structured indications
- First approval
- Canada, 2024 · United States, 2021 · European Union, 2022
- Also known as
- liso-cel
- Code names
- BMS-986387 · JCAR-017
- Brand names
Resolves to
What you can answer from here — as of May 26, 2026
Which drugs share a target with Lisocabtagene maraleucel, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account